Chemotherapy of advanced ovarian epithelial carcinoma with melphalan and levamisole: A pilot study of the Gynecologic Oncology Group
| Autor: | Charles L. Spurr, Philip J. Di Saia, Hyman B. Muss, John P. Gusdon, Howard D. Homesley, Eugene R. Heise, Judy V. Lovelace, Glenn A. Herbst, Frederick Richards |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Melphalan
medicine.medical_specialty T-Lymphocytes medicine.medical_treatment Pilot Projects Gynecologic oncology Disease Lymphocyte Activation Gastroenterology Internal medicine Humans Medicine Phytohemagglutinins Stage (cooking) Adverse effect Ovarian Neoplasms B-Lymphocytes Chemotherapy business.industry Obstetrics and Gynecology Middle Aged Levamisole Surgery Pokeweed Mitogens Toxicity Drug Therapy Combination Female business medicine.drug |
| Zdroj: | American Journal of Obstetrics and Gynecology. 141:65-70 |
| ISSN: | 0002-9378 |
| Popis: | Twenty-three patients with Stage III, Stage IV, or recurrent epithelial ovarian cancer were treated with a combination of melphalan and levamisole to determine a tolerable dosage schedule, possible adverse effects, and a general estimate of response rate and duration. In seven patients with measurable disease there were four complete responses (57%) with a median duration of 75 weeks. Two of the complete responders have had negative second-look laparotomies while the other two patients have had subsequent progression. Of 16 patients with nonmeasurable disease two have had negative second-look laparotomies and two remain progression free. Thus 8 of 23 patients (35%) had complete responses or remain progression free whereas 4 of 23 patients (17%) have had negative second-look laparotomies. No serious toxicity was encountered. Immunologic monitoring did not indicate significant immunologic reconstitution in these immunosuppressed patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|